Caris Life Sciences

Caris Life Sciences Caris Life Sciences delivers technologies to revolutionize healthcare with market-leading profiling

Caris Life Sciences® is the leading next-generation TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale, clinico-genomic database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next-generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development.

Caris Life Sciences announced the company will attend upcoming Q4 investor conferences this year. Connect with Caris to ...
11/17/2025

Caris Life Sciences announced the company will attend upcoming Q4 investor conferences this year. Connect with Caris to schedule an investor meeting and learn more about our innovative solutions to transform healthcare. https://ow.ly/jG2l50XrZRp

11/14/2025

November is Lung Cancer Awareness Month, a time to share stories of hope and progress. When Edwin Asturizaga was diagnosed with stage IV lung cancer, he nearly lost hope. But after turning to Caris for molecular profiling, things changed.

Discover how advanced insights into his cancer helped transform his treatment plan. https://ow.ly/zjzN50XrTcp

Behind every diagnosis is a pathologist. On International Pathology Day, we recognize the vital role pathologists play i...
11/12/2025

Behind every diagnosis is a pathologist. On International Pathology Day, we recognize the vital role pathologists play in advancing precision medicine and improving patient outcomes.

“Pathologists are the clinical and molecular translators connecting laboratory testing to optimal patient care. At Caris Life Sciences, our board-certified anatomic and clinical pathologists combine deep subspecialty expertise with digital pathology and AI to integrate tissue and blood profiling, resolve diagnostic uncertainty, and ensure the highest quality laboratory testing.” – Caris Chief Clinical Officer and Pathologist-in-Chief, Matthew Oberley, MD, PhD

Learn more about the expertise and innovation driving the Caris pathology team: https://ow.ly/9X3L50Xq7e2

Join Dr. Matthew Oberley as he explores three applications of whole exome and transcriptome sequencing that extend beyon...
11/11/2025

Join Dr. Matthew Oberley as he explores three applications of whole exome and transcriptome sequencing that extend beyond limited panels. From Caris GPSai for tumor origin identification to improved TMB accuracy and new COSMIC signatures, discover how using all genes can help enhance diagnostic clarity and inform treatment decisions. https://bit.ly/4hKzE1k

Heading to AMP 2025 in Boston? Visit Caris Life Sciences at Booth 1311 to connect and talk precision oncology. Schedule ...
11/09/2025

Heading to AMP 2025 in Boston? Visit Caris Life Sciences at Booth 1311 to connect and talk precision oncology. Schedule a meeting: https://bit.ly/4hKzE1k

During the World ADC 2025 Conference, Caris SVP & Chief Scientific Officer Milan Radovich, PhD, discussed how proteomic ...
11/06/2025

During the World ADC 2025 Conference, Caris SVP & Chief Scientific Officer Milan Radovich, PhD, discussed how proteomic platforms are identifying masked targets and enabling validation of ADCs using data from ~500K molecularly profiled samples.

Join Caris at the Society for Immunotherapy of Cancer (SITC) Conference to explore the next era of cancer diagnostics. S...
11/06/2025

Join Caris at the Society for Immunotherapy of Cancer (SITC) Conference to explore the next era of cancer diagnostics. Stop by booth 402 to meet our team and discover how our advanced molecular profiling solutions are helping redefine cancer care. https://ow.ly/PMME50Xnvj6

Caris Life Sciences released its third-quarter financial results today, which included 113% growth in revenue year-over-...
11/05/2025

Caris Life Sciences released its third-quarter financial results today, which included 113% growth in revenue year-over-year and an increase in full-year 2025 revenue guidance to $720-$730 million.

This updated guidance range would represent 75-77% year-over-year revenue growth for full-year 2025.

Learn more: https://ow.ly/AILA50Xnmkr

Join us during World ADC for our poster presentation, "Identification and Validation of Next Generation ADC Candidates f...
10/31/2025

Join us during World ADC for our poster presentation, "Identification and Validation of Next Generation ADC Candidates from Molecularly Profiled Patient Tissue." Stop by to learn more about the research. bit.ly/4n99ZRg

Caris announces collaborative new research identifying TET2 clonal hematopoiesis (CH) as a promising biomarker for impro...
10/29/2025

Caris announces collaborative new research identifying TET2 clonal hematopoiesis (CH) as a promising biomarker for improved response to immune checkpoint inhibitor (ICI) therapy in patients with solid tumors.

"These findings represent a major step forward in understanding how clonal hematopoiesis influences cancer immunology," said Milan Radovich, Ph.D., Senior Vice President, Chief Scientific Officer at Caris. "It further demonstrates that we are only scratching the surface on the potential applications of CH, namely a novel function of CH as a predictive therapeutic biomarker that can be used to improve patient outcomes.”

Learn more: https://ow.ly/mgFw50Xjw3M

Attending World ADC in San Diego? Join Caris SVP & Chief Scientific Officer Dr. Milan Radovich, who will discuss how inn...
10/27/2025

Attending World ADC in San Diego? Join Caris SVP & Chief Scientific Officer Dr. Milan Radovich, who will discuss how innovative proteomic platforms are uncovering masked targets and enabling the identification of high-confidence novel targets. He will also explore modality-agnostic strategies for validating ADC and other targets across indications, supported by multimodal insights from ~500K molecularly profiled tissue samples. https://bit.ly/4n99ZRg

Caris Life Sciences will attend the World ADC 2025 Conference in San Diego, California. Meet with our team to learn how ...
10/24/2025

Caris Life Sciences will attend the World ADC 2025 Conference in San Diego, California. Meet with our team to learn how Caris Discovery is redefining novel target identification by bringing world-class science to the vast Caris tissue repository. Schedule a meeting: https://bit.ly/4n99ZRg

Address

-
Irving, TX
75039

Opening Hours

Monday 7am - 7pm
Tuesday 7am - 7pm
Wednesday 7am - 7pm
Thursday 7am - 7pm
Friday 7am - 7pm

Telephone

+18889798669

Website

Alerts

Be the first to know and let us send you an email when Caris Life Sciences posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category

#WeAreCarisLS

We believe in more treatment options. Because more treatment options, can mean more time with the ones you love the most.

We’re dedicated to fulfilling the promise of precision medicine and changing the face of cancer care by providing the personalized and precise information needed to guide individualized treatment options. Learn more about our suite of market-leading molecular profiling offerings that assesses DNA, RNA and proteins to reveal the highest quality molecular blueprint so you can determine treatment options with confidence: www.carismolecularintelligence.com.